Company Overview
Cue Biopharma, Inc. (NASDAQ: CUE) is a biotechnology firm headquartered in Massachusetts that focuses on the discovery and development of therapeutic proteins for oncology and autoimmune diseases. The company’s public market data as of September 22 2026 shows a closing share price of $31.71, a 52‑week high of $45.50, a 52‑week low of $4.98, and a market capitalization of $230 million. Its price‑to‑earnings ratio is negative at ‑0.78, reflecting the company’s current operating loss.
Recent Market Performance
| Event | Date | Impact on CUE Stock |
|---|---|---|
| Pre‑market trading surge | September 21 2026 | Shares rose 41.7 %, the largest gain in the pre‑market session. |
| Positive clinical study announcement | September 21 2026 | A study on an antihistamine medication for urticaria was reported, leading to a sharp increase in share price. |
| Net short‑sale position disclosed | June 22 2026 | Trexquant Investment LP Stamford reported a net short‑sale position in CUE’s shares under the German Bundesanzeiger capital‑market section. |
The surge in September was attributed to a broader market rally and heightened geopolitical focus, as noted in a feed from feeds.feedburner.com. The clinical success announcement on the urticaria drug, reported by de.investing.com and in.investing.com, further amplified investor enthusiasm.
Regulatory and Market‑Watch Disclosures
On June 22 2026, the Bundesanzeiger published a notice in the “Kapitalmarkt” section indicating a net short‑sale position by Trexquant Investment LP Stamford in CUE’s shares (ISIN: US22978P2056). The disclosure, part of Germany’s mandatory reporting for net short‑sale positions, provides transparency to market participants about significant short positions that may influence share price movements.
Current Trading Context
- Sector: Health Care – Biotechnology
- Exchange: Nasdaq
- Currency: USD
- Recent Price: $31.71 (close)
- Recent Volatility: The share price moved from a 52‑week low of $4.98 to a recent high of $45.50, indicating significant volatility over the past year.
- Market Capitalization: $230 million
- Earnings Outlook: Negative P/E indicates ongoing investment in R&D without current profitability.
Summary
Cue Biopharma’s shares experienced a substantial pre‑market rally in September 2026 following positive clinical data for an antihistamine treatment, compounded by a broader market rally and geopolitical focus. The company’s financial metrics demonstrate high volatility and a negative earnings multiple, reflecting its status as a research‑driven biopharma entity. Regulatory disclosures such as the net short‑sale position reported in the German Bundesanzeiger provide additional insight into market sentiment and potential pressures on the stock price.
